Clinical Factors Associated with Progression to AIDS in the Italian Cohort of HIV-Positive Hemophiliacs

Summary

This study updates estimates of the cumulative incidence of AIDS among Italian patients with congenital coagulation disorders (mostly hemophiliacs), and elucidates the role of age at seroconversion, type and amount of replacement therapy, and HBV co-infection in progression. Information was collected both retrospectively and prospectively on 767 HIV-1 positive patients enrolled in the on-going national registry of patients with congenital coagulation disorders. The seroconversion date was estimated as the median point of each patient’s seroconversion interval, under a Weibull distribution applied to the overall interval. The independence of factors associated to faster progression was assessed by multivariate analysis. The cumulative incidence of AIDS was estimated using the Kaplan-Meier survival analysis at 17.0% (95% Cl = 14.1-19.9%) over an 8-year period for Italian hemophiliacs. Patients with age greater than or equal to 35 years exhibited the highest cumulative incidence of AIDS over the same time period, 32.5% (95% Cl = 22.2-42.8%). Factor IX recipients (i.e. severe B hemophiliacs) had higher cumulative incidence of AIDS (23.3% vs 14.2%, p = 0.01) than factor VIII recipients (i.e. severe A hemophiliacs), as did severe A hemophiliacs on less-than-20,000 IU/yearly of plasma-derived clotting factor concentrates, as opposed to A hemophiliacs using an average of more than 20,000 IU (18.8% vs 10.9%, p = 0.02). No statistically significant difference in progression was observed between HBsAg-positive vs HBsAg-negative hemophiliacs (10.5% vs 16.4%, p = 0.10). Virological, immunological or both reasons can account for such findings, and should be investigated from the laboratory standpoint.

• References

• 1 Schinaia N, Ghirardini A, Chiarotti F, Gringeri A, Mannucci PM. the Italian Group. Progression to AIDS among Italian HIV-seropositive haemophiliacs. AIDS 1991; 5: 385
• 2 Goedert JJ, Kessler CM, Aledort LM, Biggar RJ, Andes WA, White GC, Drummond JE, Vaidya K, Mann DL, Eyster ME, Ragni MV, Lederman MM, Cohen AR, Bray GL, Rosenberg PS, Friedman RM, Hilgartner MW, Blattner WA, Kroner B, Gail MH. A prospective study of human immunodeficiency virus type 1 infection and the development of AIDS in subjects with hemophilia. N Engl J Med 1989; 321 (17) 1141
• 3 Darby S, Doll R, Thakrar B, Rizza CR, Cox DR. Time from infection with HIV to onset of AIDS in patients with haemophilia in the UK. Stat Med 1990; 9: 681
• 4 Brettler DB, Levine PH. Factor concentrates for treatment of hemophilia: which one to choose?. Blood 1989; 73: 2067
• 5 Verani P, Mariani G, Mannucci PM, De Rossi G, Nicoletti L, Titti F, Falcione E, Pasqualetti D, Ammassari M, Gringeri A, Mandelli F, Rossi GB. Prevalence of HTLVIII/LAV antibodies in Italian asymptomatic hemophiliacs given commercial concentrates of factors VIII and IX. J Med Virol 1986; 19: 143
• 6 Bagasra O, Hauptman SP, Lischner HW, Sachs M, Pomerantz RJ. Detection of human immunodeficiency virus type 1 provirus in mononuclear cells by in situ polymerase chain reaction. N Engl J Med 1992; 326: 1385
• 7 Ghirardini A, Schinaia N, Chiarotti F, De Biasi R, Rodeghiero F, Binkin N. the GICC. Epidemiology of hemophilia and of HIV infection in Italy. J Clin Epidemiol. (accepted for publication).
• 8 Centers for Disease Control. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR 1987 36. IS
• 9 Dietrich SL, Boone DC. AIDS and congenital clotting disorders. In: AIDS: The safety of blood and blood products Petricciani JC, Gust ID, Hoppe PA, Krijnen HW. (eds). New York: Wiley and Sons: 1987: 51
• 10 Moss AR, Bacchetti P. Natural history of HIV infection (Editorial). AIDS 1989; 3: 55
• 11 Chiarotti F, Palombi M, Schinaia N, Ghirardini A, Prospero L. Effects of different parametric estimates of seroconvesion time on analysis of progression to AIDS among Italian HIV-positive hemophiliacs. Stat Med 1992; 11: 591
• 12 Dixon WJ. (ed). BMDP statistical Software 1990. Berkeley, CA: University of California Press; 1990
• 13 Machin D, Gardner MJ. Calculating confidence intervals for survival time analyses. BrMed J 1988; 296: 1369
• 14 Lee CA, Phillips A, Elford J, Miller EJ, Bofill M, Griffiths PD, Kemoff PBA. The natural history of human immunodeficiency virus infection in a haemophilic cohort. Br J Haematol 1989; 73: 228
• 15 Laurian Y, Archambeaud MP, Verroust F. AIDS in subjects with hemophilia. N Engl J Med 1990; 322 (17) 1232
• 16 Ivanoff LA, Dubay JW, Morris JF, Roberts SJ, Gutshall L, Sternberg EJ, Hunter E, Matthews TJ, Petteway Jr SR. V3 Loop Region of the HIV-1 gpl20 envelope protein is essential for virus infectivity. Virology 1992; 187: 423
• 17 Sullivan JL, Brewster FE, Brettler DB, Forsberg AD, Cheeseman SH, Byron KS, Baker SM, Willitts DL, Lew RA, Levine PH. Hemophiliac immunodeficiency: Influence of exposure to factor VIII concentrate, LAV/HTLV-III, and herpes viruses. J Pediatr 1986; 108: 504
• 18 Allain JP, Frommel D, Bosser C. the AIDS-Haemophilia French Study Group. The Role of HIV Infectivity and Composition of Factor VIII Concentrates on the Immunity of Haemophiliacs Positive for HIV Antibodies. Vox Sang 1987; 53: 37
• 19 De Biasi R, Rocino A, Miraglia E, Mastrullo L, Quirino AA. The impact of a very high purity factor VIII concentrate on the immune system of human immunodeficiency virus-infected haemophiliacs: a randomized, prospective, two-year comparison with an intermediate purity concentrate. Blood 1991; 78: 1919
• 20 Perrillo RP, Regenstein FG, Roodman ST. Chronic Hepatitis B in asymptomatic homosexual men with antibody to the human immunodeficiency virus. Ann Intern Med 1986; 105 (03) 382
• 21 Scharschmidt BF, Held MJ, Hollander HH, Read AE, Lavine JE, Veereman G, McGuire RF, Thaler MM. Hepatitis B in patients with HIV infection: Relationship to AIDS and patient survival. Ann Intern Med 1992; 117: 837